Abstract 1544P
Background
Patients (pts) with advanced gastric/gastroesophageal junction cancer that progresses on chemotherapy have poor outcomes. We investigated the safety and efficacy of camrelizumab combined with albumin-bound paclitaxel and S-1 in first-line treatment of HER-2-negative advanced gastric/gastroesophageal junction cancer.
Methods
This study was a single-arm, open-label, phase II clinical study. Eligible pts were adults with histologically confirmed HER-2 -negative advanced gastric/ gastroesophageal junction cancer. Pts participating in this study were required to detect PD-L1 expression, MSI/MMR status, and EBV virus content. Pts received camrelizumab (200 mg, day 1), S-1 (60mg/m2 bid, days 1-14), and albumin-bound paclitaxel (125mg/m2, days 1, 8) every 3 weeks. The maintenance therapy of camrelizumab (200 mg, day 1, every 3 weeks) was given to pts who did not progress after 4-6 cycles of chemotherapy until disease progression or unacceptable toxicity. Response was assessed every 6 weeks in accordance with RECIST1.1. The primary endpoint was overall response rate (ORR), and secondary endpoints included safety profile, progression free survival (PFS), overall survival (OS), and disease control rate (DCR).
Results
Between December 2020 and March 2023, a total of 28 pts were enrolled in this study. Median age was 57.5 (range: 35-71) years, and most pts were male (75.0%). Among 21 pts who were evaluated, the ORR was 71.4% (15/21) and the DCR was 95.2% (20/21). The median PFS was 9.3 months (95% Cl: 7.0-11.6), the Median follow-up time was 14.3 months (95% Cl: 9.9-18.7), and the one-year survival rate was 85.7%. The most common treatment-related adverse events of grade 3 or 4 included neutropenia (22.2%), leukopenia (22.2%), erythra (3.7%). There were no treatment-related deaths.
Conclusions
Camrelizumab plus albumin-bound paclitaxel and S-1 demonstrated promising activity and manageable safety in first-line treatment of HER-2- negative advanced gastric/gastroesophageal junction cancer.
Clinical trial identification
NCT04675866.
Editorial acknowledgement
Legal entity responsible for the study
Henan Cancer Hospital.
Funding
Jiangsu Hengrui Pharmaceutical Co. LTD.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1564P - Gut microbiome and metabolome are associated with the response to chemoradiotherapy in patients with esophageal cancer
Presenter: Mingqiang Lin
Session: Poster session 21
1565P - ERCC1 gene polymorphism influences overall survival in early oesophageal cancer: Results from the phase III MRC OEO2 randomised controlled trial
Presenter: Georgina Keogh
Session: Poster session 21
1566P - Clinical relevance of circulating tumor DNA in HER2 -positive advanced gastric cancer: Results from phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High)
Presenter: Hiroki Osumi
Session: Poster session 21
1567P - The effect of SGLT2i and DPP4i on new-onset gastric cancer and gastric diseases in type 2 diabetes mellitus: A population-based cohort study
Presenter: Hou In Chou
Session: Poster session 21
1568P - Establishment of a platform to predict radiation sensitivity in organoids derived from esophageal cancer patients
Presenter: Ga Yeon Kim
Session: Poster session 21